FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Brendan Larder

Research Profile

Living Beings

HIV-1
HIV

Physiology

Chemicals & Drugs

Disorders

HIV Infections

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
A D Revell; A Streinu-Cercel; H Tempelman; D Wang; Jori Symons; R Wood; G Alvarez-Uria; F Dewolf; L Ene; R L Hamers; H C Lane; Brendan Larder; J S Montaner; C Morrow; M Nelson
Computational models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource-limited settings.
A D Revell; D Wang; R Harrigan; R L Hamers; A M J Wensing; F Dewolf; M Nelson; A-M Geretti; Brendan Larder
Modelling response to HIV therapy without a genotype: an argument for viral load monitoring in resource-limited settings.
Dechao Wang; Brendan Larder; Andrew Revell; Julio Montaner; Richard Harrigan; Frank De Wolf; Joep Lange; Scott Wegner; Lidia Ruiz; María Jésus Pérez-Elías; Sean Emery; Jose Gatell; Antonella d'Arminio Monforte; Carlo Torti; Maurizio Zazzi; Clifford Lane
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Brendan Larder (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: A D Revell; A Streinu-Cercel; H Tempelman; D Wang; Jori Symons; R Wood; G Alvarez-Uria; F Dewolf; L Ene; R L Hamers; H C Lane; Brendan Larder; J S Montaner; C Morrow; M Nelson
Computational models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource-limited settings.
The Journal of antimicrobial chemotherapy 2013;68(6):1406-14.
2010: A D Revell; D Wang; R Harrigan; R L Hamers; A M J Wensing; F Dewolf; M Nelson; A-M Geretti; Brendan Larder
Modelling response to HIV therapy without a genotype: an argument for viral load monitoring in resource-limited settings.
The Journal of antimicrobial chemotherapy 2010;65(4):605-7.
2009: Dechao Wang; Brendan Larder; Andrew Revell; Julio Montaner; Richard Harrigan; Frank De Wolf; Joep Lange; Scott Wegner; Lidia Ruiz; María Jésus Pérez-Elías; Sean Emery; Jose Gatell; Antonella d'Arminio Monforte; Carlo Torti; Maurizio Zazzi; Clifford Lane
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy.
Artificial intelligence in medicine 2009;47(1):63-74.
2008: Brendan Larder; Dechao Wang; Andy Revell
Application of artificial neural networks for decision support in medicine.
Methods in molecular biology (Clifton, N.J.) 2008;458():123-36.
2008: Mark Mascolini; Douglas Richman; Brendan Larder; John Mellors; Charles A B Boucher
Clinical implications of resistance to antiretrovirals: new resistance technologies and interpretations.
Antiviral therapy 2008;13(2):319-34.
2007: Mark Mascolini; Charles Boucher; Brendan Larder; John Mellors; Douglas Richman
Key reports from the XV International HIV Drug Resistance Workshop 2006.
Antiviral therapy 2007;12(1):131-45.
2007: Brendan Larder; Dechao Wang; Andrew Revell; Julio Montaner; Richard Harrigan; Frank De Wolf; Joep Lange; Scott Wegner; Lidia Ruiz; María Jesús Pérez-Elías; Sean Emery; José M Gatell; Antonella d'Arminio Monforte; Carlo Torti; Maurizio Zazzi; Clifford Lane
The development of artificial neural networks to predict virological response to combination HIV therapy.
Antiviral therapy 2007;12(1):15-24.
2006: Kenneth A Curr; Snehlata Tripathi; Johan Lennerstrand; Brendan Larder; Vinayaka R Prasad
Influence of naturally occurring insertions in the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and mutation frequencies in vitro.
The Journal of general virology 2006;87(Pt 2):419-28.
2006: Charles Boucher; Brendan Larder; John Mellors; Douglas Richman
The XIVth International HIV Drug Resistance Workshop, Quebec City, Canada, June 2005.
Antiviral therapy 2006;11(5):653-65.
2004: Scott Wegner; Mark R Wallace; Naomi E Aronson; Sybil A Tasker; David L Blazes; Cindy Tamminga; Susan Fraser; Matthew J Dolan; Kevin T Stephan; Nelson L Michael; Linda L Jagodzinski; Maryanne Vahey; Joyce L Gilcrest; LaRee Tracy; Mark J Milazzo; Daniel J Murphy; Paula McKenna; Kurt Hertogs; Alex Rinehart; Brendan Larder; Deborah L Birx
Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;38(5):723-30.
2003: P Richard Harrigan; Kurt Hertogs; Werner Verbiest; Brendan Larder; Benita Yip; Zabrina L Brumme; Christopher Alexander; Jessica Tilley; Michael V O'Shaughnessy; Julio S G Montaner
Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
Antiviral therapy 2003;8(5):395-402.
2003: A Gregory DiRienzo; Victor DeGruttola; Brendan Larder; Kurt Hertogs
Non-parametric methods to predict HIV drug susceptibility phenotype from genotype.
Statistics in medicine 2003;22(17):2785-98.
2003: Dechao Wang; Brendan Larder
Enhanced prediction of lopinavir resistance from genotype by use of artificial neural networks.
The Journal of infectious diseases 2003;188(5):653-60.
2003: Paul J Weidle; Robert Downing; Catherine Sozi; Raymond Mwebaze; Gideon Rukundo; Samuel Malamba; Richard Respess; Kurt Hertogs; Brendan Larder; Dorothy Ochola; Jonathan Mermin; Badara Samb; Eve M Lackritz
Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative--Uganda.
AIDS (London, England) 2003;17 Suppl 3():S39-48.
2003: Christiane Adjé-Touré; Bilé Celestin; Debra Hanson; Thierry Roels; Kurt Hertogs; Brendan Larder; Fabien Diomande; Martine Peeters; Serge Eholié; Eve M Lackritz; Terence Chorba; John N Nkengasong
Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire.
AIDS (London, England) 2003;17 Suppl 3():S23-9.
2003: Peter R Meyer; Johan Lennerstrand; Suzanne E Matsuura; Brendan Larder; Walter A Scott
Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation.
Journal of virology 2003;77(6):3871-7.
2003: Martin Stürmer; Schlomo Staszewski; Hans Wilhelm Doerr; Brendan Larder; Stuart Bloor; Kurt Hertogs
Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214.
Antimicrobial agents and chemotherapy 2003;47(1):54-61.
2002: Philip P Chamberlain; Jingshan Ren; Charles E Nichols; L Douglas; Johan Lennerstrand; Brendan Larder; David I Stuart; David K Stammers
Crystal structures of Zidovudine- or Lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215.
Journal of virology 2002;76(19):10015-9.
2002: P Richard Harrigan; Mahboob Salim; David K Stammers; Brian Wynhoven; Zabrina L Brumme; Paula McKenna; Brendan Larder; SD Kemp
A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance.
Journal of virology 2002;76(13):6836-40.
2002: Laura Romano; Giulietta Venturi; Stuart Bloor; Richard Harrigan; Brendan Larder; Jennifer C Major; Maurizio Zazzi
Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118.
The Journal of infectious diseases 2002;185(7):898-904.
2002: P Richard Harrigan; M Miller; Paula McKenna; Zabrina L Brumme; Brendan Larder
Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.
Antimicrobial agents and chemotherapy 2002;46(4):1067-72.
2002: P Richard Harrigan; Brendan Larder
Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates.
Antimicrobial agents and chemotherapy 2002;46(3):909-12.
2002: Wataru Sugiura; Zene Matsuda; Yoshiyuki Yokomaku; Kurt Hertogs; Brendan Larder; Tsuyoshi Oishi; Aiko Okano; Teiichirou Shiino; Masashi Tatsumi; Masakazu Matsuda; Hanae Abumi; Noboru Takata; Satoshi Shirahata; Kaneo Yamada; Hiroshi Yoshikura; Yoshiyuki Nagai
Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1.
Antimicrobial agents and chemotherapy 2002;46(3):708-15.
2002: P J Easterbrook; Kurt Hertogs; A Waters; B Wills; B G Gazzard; Brendan Larder
Low prevalence of antiretroviral drug resistance among HIV-1 seroconverters in London, 1984-1991.
The Journal of infection 2002;44(2):88-91.
2002: Shoukat H Qari; Richard Respess; Hillard Weinstock; Elise M Beltrami; Kurt Hertogs; Brendan Larder; Christos J Petropoulos; Nicholas Hellmann; Walid Heneine
Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1.
Journal of clinical microbiology 2002;40(1):31-5.
2001: P Richard Harrigan; Julio S G Montaner; Scott Wegner; Werner Verbiest; Veronica Miller; R Wood; Brendan Larder
World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing.
AIDS (London, England) 2001;15(13):1671-7.
2001: Johan Lennerstrand; Kurt Hertogs; David K Stammers; Brendan Larder
Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants.
Journal of virology 2001;75(15):7202-5.
2001: Johan Lennerstrand; David K Stammers; Brendan Larder
Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine.
Antimicrobial agents and chemotherapy 2001;45(7):2144-6.
2001: Lee Bacheler; S Jeffrey; G Hanna; Richard T D'Aquila; L Wallace; Kelly Logue; Beverly C Cordova; Kurt Hertogs; Brendan Larder; R Buckery; D Baker; Karen Gallagher; H Scarnati; R Tritch; C Rizzo
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Journal of virology 2001;75(11):4999-5008.
2001: Christiane Adjé; Rachanee Cheingsong; Thierry Roels; Chantal Maurice; Gaston Djomand; Werner Verbiest; Kurt Hertogs; Brendan Larder; Bondo Monga; M Peeters; SP Eholie; E Bissagene; Mamadou B Coulibaly; Richard Respess; Stefan Z Wiktor; Terence Chorba; John N Nkengasong
High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.
Journal of acquired immune deficiency syndromes (1999) 2001;26(5):501-6.
2001: Paul J Weidle; Cissy Kityo; Peter Mugyenyi; Robert Downing; Anthony Kebba; Danuta Pieniazek; Richard Respess; Kurt Hertogs; Veronique De Vroey; Pascale Dehertogh; Stuart Bloor; Brendan Larder; Eve M Lackritz
Resistance to antiretroviral therapy among patients in Uganda.
Journal of acquired immune deficiency syndromes (1999) 2001;26(5):495-500.
2001: Robert W Shafer; Kurt Hertogs; Andrew R Zolopa; Ann Warford; Stuart Bloor; Bradley J Betts; Thomas C Merigan; R Harrigan; Brendan Larder
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients.
Journal of clinical microbiology 2001;39(4):1522-9.
2001: Werner Verbiest; S Brown; C Cohen; Marcus Conant; K Henry; S Hunt; Michael Sension; A Stein; R Stryker; M Thompson; P Schel; R Van Den Broeck; Stuart Bloor; TM Alcorn; M Van Houtte; Brendan Larder; Kurt Hertogs
Prevalence of HIV-1 drug resistance in antiretroviral-naive patients: a prospective study.
AIDS (London, England) 2001;15(5):647-50.
2001: Anne-Mieke Vandamme; F Houyez; D Bànhegyi; Bonaventura Clotet; G De Schrijver; Koen De Smet; W W Hall; R Harrigan; N Hellmann; Kurt Hertogs; C Holtzer; Brendan Larder; D Pillay; E Race; Jean-Claude Schmit; R Schuurman; E Schulse; Anders Sönnerborg; V Miller
Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up.
Antiviral therapy 2001;6(1):21-39.
2001: Fernando Dronda; José L Casado; Santiago Moreno; Kurt Hertogs; I García-Arata; Antonio Antela; María Jesús Pérez-Elías; L Ruiz; Brendan Larder
Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene.
AIDS research and human retroviruses 2001;17(3):211-5.
2001: Elena Caride; Kurt Hertogs; Brendan Larder; Pascale Dehertogh; Rodrigo M Brindeiro; Elizabeth S Machado; Carlos Alberto M de Sá; Walter A Eyer-Silva; Fernando Samuel Sion; L F Passioni; J A Menezes; Alexandre Calazans; Amilcar Tanuri
Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART.
Virus genes 2001;23(2):193-202.
2001: Veronica Miller; Brendan Larder
Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Antiviral therapy 2001;6 Suppl 3():25-44.
2001: Michael A Poles; Julie Elliott; J Vingerhoets; Lieve Michiels; A Scholliers; Stuart Bloor; Brendan Larder; Kurt Hertogs; Peter A Anton
Despite high concordance, distinct mutational and phenotypic drug resistance profiles in human immunodeficiency virus type 1 RNA are observed in gastrointestinal mucosal biopsy specimens and peripheral blood mononuclear cells compared with plasma.
The Journal of infectious diseases 2001;183(1):143-8.
2000: Veronica Miller; Caroline Sabin; Kurt Hertogs; Stuart Bloor; Javier Martinez-Picado; Richard T D'Aquila; Brendan Larder; Thomas Lutz; Peter Gute; Eckhart Weidmann; Holger Rabenau; Andrew Phillips; Schlomo Staszewski
Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure.
AIDS (London, England) 2000;14(18):2857-67.
2000: Elena Caride; Rodrigo M Brindeiro; Kurt Hertogs; Brendan Larder; Pascale Dehertogh; Elizabeth S Machado; Carlos Alberto M de Sá; Walter A Eyer-Silva; Fernando Samuel Sion; L F Passioni; J A Menezes; Alexandre Calazans; Amilcar Tanuri
Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.
Virology 2000;275(1):107-15.
2000: Brendan Larder; Kurt Hertogs; Stuart Bloor; Christel Van den Eynde; W DeCian; Y Wang; W W Freimuth; G Tarpley
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.
AIDS (London, England) 2000;14(13):1943-8.
2000: Kurt Hertogs; Stuart Bloor; SD Kemp; Christel Van den Eynde; TM Alcorn; Rudi Pauwels; M Van Houtte; Schlomo Staszewski; Veronica Miller; Brendan Larder
Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.
AIDS (London, England) 2000;14(9):1203-10.
2000: Scott Wegner; Stephanie K Brodine; John R Mascola; Sybil A Tasker; Richard A Shaffer; Monica J Starkey; Anthony J Barile; G J Martin; Naomi E Aronson; W W Emmons; Kevin T Stephan; Stuart Bloor; J Vingerhoets; Kurt Hertogs; Brendan Larder
Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel.
AIDS (London, England) 2000;14(8):1009-15.
2000: Veronica Miller; Alessandro Cozzi-Lepri; Kurt Hertogs; Peter Gute; Brendan Larder; Stuart Bloor; Stephan Klauke; Holger Rabenau; Andrew Phillips; Schlomo Staszewski
HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort.
Antiviral therapy 2000;5(1):49-55.
2000: P Richard Harrigan; Chris Stone; Philip Griffin; I Nájera; Stuart Bloor; S Kemp; Margaret Tisdale; Brendan Larder
Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group.
The Journal of infectious diseases 2000;181(3):912-20.
2000: Kurt Hertogs; Stuart Bloor; Veronique De Vroey; Christel Van den Eynde; Pascale Dehertogh; A Van Cauwenberge; Martin Stürmer; TM Alcorn; Scott Wegner; M Van Houtte; Veronica Miller; Brendan Larder
A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V.
Antimicrobial agents and chemotherapy 2000;44(3):568-73.
2000: José L Casado; Kurt Hertogs; Lidia Ruiz; Fernando Dronda; A Van Cauwenberge; Albert Arno; I Garcia-Arata; Stuart Bloor; Anna Bonjoch; J Blazquez; Bonaventura Clotet; Brendan Larder
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.
AIDS (London, England) 2000;14(2):F1-7.
1999: P Richard Harrigan; Kurt Hertogs; Werner Verbiest; Rudi Pauwels; Brendan Larder; S Kemp; Stuart Bloor; Benita Yip; Hogg Robert; C Alexander; Julio S G Montaner
Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.
AIDS (London, England) 1999;13(14):1863-71.
1999: DR Churchill; AS Pym; Sarah Galpin; Russell B Foxall; C Stainsby; John R Clarke; S Kaye; Stuart Bloor; Brendan Larder; B Wills; E Sun; Abdel G Babiker; D J Back; Jonathan N Weber
The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.
AIDS research and human retroviruses 1999;15(13):1181-9.
1999: Brendan Larder; Stuart Bloor; SD Kemp; Kurt Hertogs; R L Desmet; Veronica Miller; M Sturmer; Schlomo Staszewski; J Ren; David K Stammers; D I Stuart; Rudi Pauwels
A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.
Antimicrobial agents and chemotherapy 1999;43(8):1961-7.
1999: Maryanne Vahey; Martin E Nau; S Barrick; J D Cooley; R Sawyer; A A Sleeker; P Vickerman; Stuart Bloor; Brendan Larder; Nelson L Michael; Scott Wegner
Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms.
Journal of clinical microbiology 1999;37(8):2533-7.
1998: Veronica Miller; Andrew Phillips; Carsten Rottmann; Schlomo Staszewski; Rudi Pauwels; Kurt Hertogs; Marie-Pierre de Bethune; SD Kemp; Stuart Bloor; P Richard Harrigan; Brendan Larder
Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure.
The Journal of infectious diseases 1998;177(6):1521-32.
1998: SD Kemp; C Shi; Stuart Bloor; P Richard Harrigan; J W Mellors; Brendan Larder
A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine.
Journal of virology 1998;72(6):5093-8.
1998: Veronica Miller; Martin Stürmer; Schlomo Staszewski; Bettina Gröschel; Kurt Hertogs; Marie-Pierre de Bethune; Rudi Pauwels; P Richard Harrigan; Stuart Bloor; SD Kemp; Brendan Larder
The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
AIDS (London, England) 1998;12(7):705-12.
1998: P Richard Harrigan; Stuart Bloor; Brendan Larder
Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.
Journal of virology 1998;72(5):3773-8.
1998: Kurt Hertogs; Marie-Pierre de Bethune; Veronica Miller; Tania Ivens; P Schel; A Van Cauwenberge; Christel Van den Eynde; V Van Gerwen; Hilde Azijn; M Van Houtte; F Peeters; Schlomo Staszewski; Marcus Conant; Stuart Bloor; S Kemp; Brendan Larder; Rudi Pauwels
A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.
Antimicrobial agents and chemotherapy 1998;42(2):269-76.
1996: P Richard Harrigan; I Kinghorn; Stuart Bloor; SD Kemp; I Nájera; A Kohli; Brendan Larder
Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
Journal of virology 1996;70(9):5930-4.
1996: Brendan Larder; A Kohli; Stuart Bloor; SD Kemp; P Richard Harrigan; Robert T Schooley; J M Lange; K N Pennington; Marty St Clair
Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
Journal of virology 1996;70(9):5922-9.
1996: Robert T Schooley; C Ramirez-Ronda; J M Lange; D A Cooper; J Lavelle; L Lefkowitz; M Moore; Brendan Larder; Marty St Clair; J W Mulder; R McKinnis; K N Pennington; P Richard Harrigan; I Kinghorn; H Steel; J F Rooney
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
The Journal of infectious diseases 1996;173(6):1354-66.
1995: Brendan Larder; SD Kemp; P Richard Harrigan
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
Science (New York, N.Y.) 1995;269(5224):696-9.
1995: Kellam Paul; Brendan Larder
Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance.
Journal of virology 1995;69(2):669-74.
1994: S F Lacey; Brendan Larder
Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture.
Antimicrobial agents and chemotherapy 1994;38(6):1428-32.
1994: Brendan Larder
Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
The Journal of general virology 1994;75 ( Pt 5)():951-7.
1994: S F Lacey; Brendan Larder
Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance.
Journal of virology 1994;68(5):3421-4.
1994: Kellam Paul; Charles A B Boucher; J M Tijnagel; Brendan Larder
Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance.
The Journal of general virology 1994;75 ( Pt 2)():341-51.
1994: Kellam Paul; Brendan Larder
Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates.
Antimicrobial agents and chemotherapy 1994;38(1):23-30.
1993: Brendan Larder; A Kohli; Kellam Paul; SD Kemp; M Kronick; R D Henfrey
Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing.
Nature 1993;365(6447):671-3.
1993: Brendan Larder; Kellam Paul; SD Kemp
Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
Nature 1993;365(6445):451-3.
1993: Charles A B Boucher; Remko van Leeuwen; Kellam Paul; Pauline Schipper; J Tijnagel; Joep M A Lange; Brendan Larder
Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates.
Antimicrobial agents and chemotherapy 1993;37(7):1525-30.
1993: M Tisdale; SD Kemp; N R Parry; Brendan Larder
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(12):5653-6.
1992: Brendan Larder
3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors.
Antimicrobial agents and chemotherapy 1992;36(12):2664-9.
1992: Charles A B Boucher; Joep M A Lange; Frank Miedema; Gerrit Jan Weverling; M Koot; Jan W Mulder; Jaap Goudsmit; Kellam Paul; Brendan Larder; M Tersmette
HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.
AIDS (London, England) 1992;6(11):1259-64.
1992: S F Lacey; J E Reardon; E S Furfine; T A Kunkel; K Bebenek; K A Eckert; SD Kemp; Brendan Larder
Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3'-azido-3'-deoxythymidine.
The Journal of biological chemistry 1992;267(22):15789-94.
1992: G Darby; Brendan Larder
The clinical significance of antiviral drug resistance.
Research in virology 1992;143(2):116-20.
1992: Kellam Paul; Charles A B Boucher; Brendan Larder
Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(5):1934-8.
1992: Charles A B Boucher; E O'Sullivan; Jan W Mulder; C Ramautarsing; Kellam Paul; G Darby; Joep M A Lange; Jaap Goudsmit; Brendan Larder
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.
The Journal of infectious diseases 1992;165(1):105-10.
1991: Brendan Larder; K E Coates; SD Kemp
Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture.
Journal of virology 1991;65(10):5232-6.
1991: Marty St Clair; J L Martin; G Tudor-Williams; M C Bach; CL Vavro; D M King; Kellam Paul; SD Kemp; Brendan Larder
Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
Science (New York, N.Y.) 1991;253(5027):1557-9.
1991: D M Lowe; V Parmar; SD Kemp; Brendan Larder
Mutational analysis of two conserved sequence motifs in HIV-1 reverse transcriptase.
FEBS letters 1991;282(2):231-4.
1991: Brendan Larder; Kellam Paul; SD Kemp
Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes.
AIDS (London, England) 1991;5(2):137-44.
1991: M Tisdale; T Schulze; Brendan Larder; K Moelling
Mutations within the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase abolish virus infectivity.
The Journal of general virology 1991;72 ( Pt 1)():59-66.
1990: Charles A B Boucher; M Tersmette; Joep M A Lange; Kellam Paul; R E de Goede; Jan W Mulder; G Darby; Jaap Goudsmit; Brendan Larder
Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy.
Lancet 1990;336(8715):585-90.
1990: Brendan Larder; B Chesebro; D D Richman
Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay.
Antimicrobial agents and chemotherapy 1990;34(3):436-41.
1989: Brendan Larder; SD Kemp
Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
Science (New York, N.Y.) 1989;246(4934):1155-8.
1989: Brendan Larder; SD Kemp; D J Purifoy
Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(13):4803-7.
1989: Brendan Larder; G Darby; D D Richman
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
Science (New York, N.Y.) 1989;243(4899):1731-4.
1989: P Collins; Brendan Larder; N M Oliver; S Kemp; I W Smith; G Darby
Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir.
The Journal of general virology 1989;70 ( Pt 2)():375-82.
1989: M Tisdale; Brendan Larder; D M Lowe; David K Stammers; D J Purifoy; P Ertl; C Bradley; S Kemp; G K Darby; K L Powell
Structural characterization of HIV reverse transcriptase: a target for the design of specific virus inhibitors.
The Journal of antimicrobial chemotherapy 1989;23 Suppl A():47-54.
1988: D M Lowe; A Aitken; C Bradley; G K Darby; Brendan Larder; K L Powell; D J Purifoy; M Tisdale; David K Stammers
HIV-1 reverse transcriptase: crystallization and analysis of domain structure by limited proteolysis.
Biochemistry 1988;27(25):8884-9.
1988: M Tisdale; P Ertl; Brendan Larder; D J Purifoy; G Darby; K L Powell
Characterization of human immunodeficiency virus type 1 reverse transcriptase by using monoclonal antibodies: role of the C terminus in antibody reactivity and enzyme function.
Journal of virology 1988;62(10):3662-7.
1988: Brendan Larder; D J Purifoy; K L Powell; C Bradley; S Kemp; M Tisdale; P Ertl; G K Darby; David K Stammers
Structural studies of the acquired immunodeficiency syndrome virus reverse transcriptase.
The American journal of medicine 1988;85(2A):173-5.
1987: Brendan Larder; D Purifoy; K Powell; G Darby
AIDS virus reverse transcriptase defined by high level expression in Escherichia coli.
The EMBO journal 1987;6(10):3133-7.
1987: Brendan Larder; D J Purifoy; K L Powell; G Darby
Site-specific mutagenesis of AIDS virus reverse transcriptase.
Nature 1987;327(6124):716-7.
1987: Brendan Larder; SD Kemp; G Darby
Related functional domains in virus DNA polymerases.
The EMBO journal 1987;6(1):169-75.
1986: Brendan Larder; J J Lisle; G Darby
Restoration of wild-type pathogenicity to an attenuated DNA polymerase mutant of herpes simplex virus type 1.
The Journal of general virology 1986;67 ( Pt 11)():2501-6.
1986: Brendan Larder; G Darby
Susceptibility to other antiherpes drugs of pathogenic variants of herpes simplex virus selected for resistance to acyclovir.
Antimicrobial agents and chemotherapy 1986;29(5):894-8.
1985: Brendan Larder; G Darby
Selection and characterisation of acyclovir-resistant herpes simplex virus type 1 mutants inducing altered DNA polymerase activities.
Virology 1985;146(2):262-71.
1984: G Darby; M J Churcher; Brendan Larder
Cooperative effects between two acyclovir resistance loci in herpes simplex virus.
Journal of virology 1984;50(3):838-46.
1984: Brendan Larder; G Darby
Virus drug-resistance: mechanisms and consequences.
Antiviral research 1984;4(1-2):1-42.
1983: Brendan Larder; Y C Cheng; G Darby
Characterization of abnormal thymidine kinases induced by drug-resistant strains of herpes simplex virus type 1.
The Journal of general virology 1983;64 Pt 3():523-32.
1983: Brendan Larder; D Derse; Y C Cheng; G Darby
Properties of purified enzymes induced by pathogenic drug-resistant mutants of herpes simplex virus. Evidence for virus variants expressing normal DNA polymerase and altered thymidine kinase.
The Journal of biological chemistry 1983;258(3):2027-33.
1982: H J Field; Brendan Larder; G Darby
Isolation and characterization of acyclovir-resistant strains of herpes simplex virus.
The American journal of medicine 1982;73(1A):369-71.
1982: Brendan Larder; G Darby
Properties of a novel thymidine kinase induced by an acyclovir-resistant herpes simplex virus type 1 mutant.
Journal of virology 1982;42(2):649-58.
1980: G Darby; Brendan Larder; Kenneth F Bastow; H J Field
Sensitivity of viruses to phosphorylated 9-(2-hydroxyethoxymethyl)guanine revealed in TK-transformed cells.
The Journal of general virology 1980;48(Pt 2):451-4.